Firebrick Pharma Strengthens IP Portfolio While Advancing Global Growth Plans
Firebrick Pharma Limited (ASX: FRE) reported steady operational progress during the June 2026 quarter, highlighted by the expansion of its intellectual property portfolio and continued commercialisation of its Nasodine product range. The company secured two additional patents, including approval in Canada for its pandemic-use patent and a New Zealand grant for its improved virucidal formulations, strengthening protection across multiple international markets. Sales development also remained positive, with adjusted FY26 cash sales rising 43% year-on-year after excluding a one-off prior-year receipt.
Financially, Firebrick ended the quarter with AU$1.322 million in cash after recording an operating cash outflow of AU$768,000. The company noted that quarterly expenses included several prepayments and one-off costs, while management expects lower operating cash outflows in the coming quarter. Having completed a AU$1.5 million placement earlier in 2026, Firebrick stated that it retains the capacity to raise additional capital if required while continuing to expand the Nasodine portfolio into new international markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Firebrick Pharma Strengthens IP Portfolio While Advancing Global Growth Plans
Firebrick Pharma Limited (ASX: FRE) reported steady operational progress during the June 2026 quarter, highlighted by the expansion of its intellectual property portfolio and continued commercialisation of its Nasodine product range. The company secured two additional patents, including approval in Canada for its pandemic-use patent and a New Zealand grant for its improved virucidal formulations, strengthening protection across multiple international markets. Sales development also remained positive, with adjusted FY26 cash sales rising 43% year-on-year after excluding a one-off prior-year receipt.
Financially, Firebrick ended the quarter with AU$1.322 million in cash after recording an operating cash outflow of AU$768,000. The company noted that quarterly expenses included several prepayments and one-off costs, while management expects lower operating cash outflows in the coming quarter. Having completed a AU$1.5 million placement earlier in 2026, Firebrick stated that it retains the capacity to raise additional capital if required while continuing to expand the Nasodine portfolio into new international markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au